The VIPS process involved in-depth research, stakeholder consultations, and development and application of a methodology capable of evaluating a variety of technologies at different stages along the product development pipeline continuum. There is increasing recognition of the need to employ targeted solutions to extend vaccine access to reach the unreached. Vaccine product innovations offer important means to simplify logistics, increase the acceptability and safety of immunisation, minimise missed opportunities, and facilitate outreach. Innovative approaches are needed to help to address immunisation barriers and achieve immunisation coverage and equity goals. The Vaccine Innovation Prioritisation Strategy (VIPS) represents an unprecedented three-year collaboration between the Gavi Secretariat, World Health Organization (WHO), Bill & Melinda Gates Foundation (BMGF), United Nations Children’s Fund (UNICEF) and PATH– known as the VIPS Alliance - to develop a single integrated framework to evaluate and prioritise vaccine product innovations and to drive these innovations forward.
0 kommentar(er)
